01 Jun 2025
11m
ASCO 2025: Arvinas CEO John Houston discusses the phase 3 study result of the PROTAC Vepdegestrant in breast cancer, the first phase 3 readout of its kind for the field of protein degradation
BiotechTV - News
Open in Podwise to generate AI notes
Sign in to process this episode and unlock summaries, transcripts, highlights and translations.
Shownotes are not generated by Podwise.